GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Beneish M-Score

CSL (CMXHF) Beneish M-Score : -1.13 (As of May. 04, 2024)


View and export this data going back to 2009. Start your Free Trial

What is CSL Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.13 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for CSL's Beneish M-Score or its related term are showing as below:

CMXHF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.5   Max: -1.13
Current: -1.13

During the past 13 years, the highest Beneish M-Score of CSL was -1.13. The lowest was -2.85. And the median was -2.50.


CSL Beneish M-Score Historical Data

The historical data trend for CSL's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Beneish M-Score Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.13 -2.68 -2.85 -2.58 -1.13

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.58 - -1.13 -

Competitive Comparison of CSL's Beneish M-Score

For the Biotechnology subindustry, CSL's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CSL's Beneish M-Score falls into.



CSL Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CSL for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.023+0.528 * 1.06+0.404 * 3.8545+0.892 * 1.2555+0.115 * 0.7511
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2271+4.679 * -0.014986-0.327 * 1.0059
=-1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $1,905 Mil.
Revenue was $13,174 Mil.
Gross Profit was $6,708 Mil.
Total Current Assets was $9,259 Mil.
Total Assets was $36,234 Mil.
Property, Plant and Equipment(Net PPE) was $9,352 Mil.
Depreciation, Depletion and Amortization(DDA) was $831 Mil.
Selling, General, & Admin. Expense(SGA) was $2,540 Mil.
Total Current Liabilities was $4,608 Mil.
Long-Term Debt & Capital Lease Obligation was $11,172 Mil.
Net Income was $2,194 Mil.
Gross Profit was $136 Mil.
Cash Flow from Operations was $2,601 Mil.
Total Receivables was $1,483 Mil.
Revenue was $10,493 Mil.
Gross Profit was $5,664 Mil.
Total Current Assets was $16,461 Mil.
Total Assets was $28,346 Mil.
Property, Plant and Equipment(Net PPE) was $8,309 Mil.
Depreciation, Depletion and Amortization(DDA) was $543 Mil.
Selling, General, & Admin. Expense(SGA) was $1,649 Mil.
Total Current Liabilities was $7,108 Mil.
Long-Term Debt & Capital Lease Obligation was $5,164 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1905 / 13174) / (1483.2 / 10493.1)
=0.144603 / 0.14135
=1.023

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5663.5 / 10493.1) / (6708 / 13174)
=0.539736 / 0.509185
=1.06

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9259 + 9352) / 36234) / (1 - (16460.7 + 8308.6) / 28346)
=0.486366 / 0.12618
=3.8545

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=13174 / 10493.1
=1.2555

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(542.5 / (542.5 + 8308.6)) / (831 / (831 + 9352))
=0.061292 / 0.081607
=0.7511

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2540 / 13174) / (1648.7 / 10493.1)
=0.192804 / 0.157122
=1.2271

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11172 + 4608) / 36234) / ((5163.8 + 7108.2) / 28346)
=0.435503 / 0.432936
=1.0059

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2194 - 136 - 2601) / 36234
=-0.014986

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CSL has a M-score of -1.19 signals that the company is likely to be a manipulator.


CSL (CMXHF) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

CSL (CMXHF) Headlines

From GuruFocus